Stopping Ozempic With PCOS (Now PMOS): What Comes Back, and How Fast

The weight came off. Your period turned up on its own, possibly for the first time in years. And now the prescription is ending — the cost, a shortage, side effects you're tired of, or because you always meant this to be temporary — and the question sitting underneath all of it is whether you're about to watch the whole thing reverse.

The honest answer has two halves. The general obesity research is fairly clear about what happens to the weight, and it isn't reassuring. The PMOS-specific research is one small study, and it points somewhere more interesting than the headlines do.

PCOS is now PMOS — Polyendocrine Metabolic Ovarian Syndrome, renamed by Lancet consensus in May 2026. Both names are in use here because both are still in use everywhere else.

How much weight comes back, and how fast

In March 2026, eClinicalMedicine published the most complete answer we have: a systematic review and nonlinear meta-regression pooling six randomized trials and 3,236 participants who stopped a GLP-1 receptor agonist.

One year after cessation, 60% of the weight lost during treatment had been regained. The modeled curve plateaus at 75.3% (95% CI 68.9–81.6) — meaning about three-quarters of the loss eventually comes back, but not all of it. The half-life was 23.0 weeks, so most of the movement happens in the first six months and then decelerates.

The longest individual follow-up says the same thing. The STEP 1 extension, published in Diabetes, Obesity and Metabolism in 2022, tracked people a full year after withdrawal of semaglutide 2.4 mg. Mean weight loss on treatment was 17.3%. Twelve months off it, 11.6 percentage points had returned, leaving participants 5.6% below where they started. Cardiometabolic markers — blood pressure, lipids, glycemia — drifted back toward baseline alongside the weight.

So: not back to square one, and not "kept it off" either. The plateau lands below your starting point, which is a real if modest result, and it's the number worth planning around rather than either of the stories the internet tells.

Do PMOS symptoms come back too?

Probably, and for a reason that's worth understanding rather than fearing.

GLP-1 drugs don't act on the ovaries. What they change in PMOS is weight and insulin signaling, and the hormonal improvements follow from there — lower insulin means less ovarian androgen production, which is why cycles often regularize and why the 2026 evidence on GLP-1s in PMOS is genuinely encouraging. But an effect that runs through insulin resistance is an effect that tracks insulin resistance. As weight and metabolic markers drift back, the reasonable expectation is that cycle regularity and androgen-driven symptoms drift with them.

Here's what we can't tell you: almost nobody has measured it. The discontinuation literature is overwhelmingly general-obesity, and it reports scales and lipid panels, not menstrual cycles or testosterone. A 2025 scoping review of GLP-1 receptor agonists in PCOS found exactly one study that followed patients after stopping.

That one study is worth the rest of this article.

The only study that followed PMOS patients off semaglutide

Jensterle and colleagues, Frontiers in Endocrinology, 2024. Twenty-five women with PMOS and obesity, mean age 33.7, took semaglutide 1.0 mg weekly for 16 weeks alongside metformin 2000 mg daily. Median weight fell from 101 kg to 92 kg. Free testosterone dropped by roughly a third.

Then the semaglutide stopped. The metformin and the lifestyle program didn't. Two years later, median weight was 95 kg — about one-third of the semaglutide-induced loss regained, against the ~75% the pooled cessation data predicts. The difference from baseline was still statistically significant (p=0.003), and 84% of the group remained below their starting weight. The androgen improvement did not significantly deteriorate over those two years.

The limitations are large and we'd rather state them than bury them. Twenty-five women. Observational, with no control group, so nothing here proves metformin caused the difference — these women may simply have been a group who did well. The semaglutide dose was 1.0 mg, the diabetes-range dose, not the 2.4 mg used in STEP 1, so the loss to be regained was smaller to begin with. You cannot build a protocol on this.

What you can do is notice that the one cohort studied off semaglutide was a cohort that never came off metabolic treatment entirely — and it regained less than half what the general curve predicts.

The regain is pharmacology, not discipline

Worth saying plainly, because a lot of people stop these drugs and conclude they failed.

Appetite and satiety signaling return to roughly where they were once the drug clears. The "food noise" that went quiet comes back. Weight loss itself lowers resting energy expenditure, so the body defends the lower weight less than it defends the higher one. PMOS adds insulin resistance on top of all of that, which is the same headwind that made the weight difficult in the first place.

A drug that works while you take it stops working when you stop taking it. That's the finding across the entire obesity literature, and it's why the STEP 1 authors described their own results as confirming the chronicity of obesity rather than as a disappointment.

What appears to reduce the regain

Two things have data behind them, and one obvious thing doesn't.

Exercise that's already established before you stop. A 2024 post-treatment analysis in eClinicalMedicine followed people for a year after a one-year weight-maintenance trial. Regain was 6.0 kg larger after stopping liraglutide alone than after stopping a supervised exercise program (95% CI 2.1–10.0). People who'd done both landed in between, not significantly different from exercise alone. The signal is that a physical-activity habit survives withdrawal in a way that a drug effect cannot — but note the trial built that habit during treatment, not after.

A metabolic bridge. The Jensterle pattern — staying on metformin through and after the taper — is the only PMOS-specific version of this idea anyone has published. Metformin is also first-line in the PMOS guidelines for metabolic outcomes anyway, so for many people it isn't an extra intervention so much as the one that was there first. If metformin is off the table for you, the inositol comparison is the relevant conversation, though nobody has studied inositol as a post-GLP-1 bridge and we won't pretend otherwise.

Tapering slowly rather than stopping abruptly is widely recommended and, as far as we can find, entirely untested in trials. It may well help. There's no evidence either way, and anyone telling you there is hasn't checked.

If you're planning to stop

Set the maintenance up before the last dose, not after it. That's the practical reading of the exercise data — what protected people was already in place when the drug came out.

Decide what you're actually measuring. Weight will move; that's predictable and now roughly quantified. Cycle length, skin, and hair are the PMOS outcomes worth tracking, and they'll tell you more about whether the underlying picture is holding than the scale will.

Get the reason for stopping onto the table with your clinician rather than deciding alone — cost, side effects, and stopping in order to conceive are three completely different situations with different timelines, and the last one has specific guidance attached to it. GLP-1s are prescribed off-label for PMOS in most places, which makes the conversation more important, not less.

And it's worth knowing which version of PMOS you're managing before you plan around it. Insulin resistance drives a large share of cases and is the mechanism GLP-1s act through — but androgen-dominant and ovulation-driven presentations behave differently on the way down and on the way back up. Our free assessment reads your symptom pattern and points to the driver most likely behind yours in about five minutes — which makes the post-GLP-1 plan a lot less of a guess.

---

We inform; we don't diagnose or prescribe. Semaglutide, tirzepatide, and metformin are prescription medications — starting, stopping, or tapering any of them is a decision for you and your clinician.

Sources: Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression, eClinicalMedicine, March 2026 · Wilding et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022 (PMC9542252) · Jensterle et al., The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study, Frontiers in Endocrinology 2024;15:1366940 (PMID 38665260) · Jensen et al., Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment, eClinicalMedicine 2024;69:102475 · The Effects of GLP-1 Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review (PMC12551431).